Immunology Focus Group Newsletter
February 2019, Number 2
About Us Speakers Investigators Sponsors Opportunities Resources Forum Contact Us
KCI Grand Rounds - February 2019
Pawel Kalinski
Lecture: 4:30 pm
Wertz Auditorium (Hudson Webber Cancer Research Center, 2nd floor)
4100 John R., Detroit, MI 48201

Supported by:
Barbara Ann Karmanos Cancer Institute

Dendritic Cells and Combinatorial Adjuvants
in the Therapy of PD-1 Non-responsive Tumors

Pawel Kalinski, M.D., Ph.D.
Vice Chair for Translational Research, Department of Medicine
Director of Cancer Vaccine and Dendritic Cell Therapies, Center for Immunotherapy
Co-Leader, Tumor Immunology & Immunotherapy Program
Rustum Family Professor for Molecular Therapeutics and Translational Research
Professor of Oncology
Roswell Park Comprehensive Cancer Center

Hosts: Wei-Zen Wei, PhD
Barbara Ann Karmanos Cancer Institute
Department of Oncology, Wayne State University
Dr. Kalinski's research evaluates the interactions of the immune cells with lymph node and tumor microenvironments, aiming to incorporate immunotherapy into comprehensive cancer care. He has established that dendritic cells (DCs) “memorize” the inflammatory signals received during their development and translate them into distinct patterns of immunity induced in the draining lymph nodes. These findings have led to the concept of “signal 3” as the third signal (additional to antigenic- and costimulatory signals) delivered by DCs to T lymphocytes and regulating T cell effector functions. The associated concepts of functional polarization of DCs and polarized DCs subsets have resulted in clinical applications of type-1 polarized DCs in order to selectively promote type-1 immunity against cancer. His follow up studies have demonstrated that differentially-polarized DCs secrete different sets of chemokines and that DC polarization can be used to selectively direct vaccine antigens to naïve, effector and memory T cells, rather than to undesirable Treg cells. Extending these studies, he has developed combinatorial adjuvants to augment the entry of immune cells into lymph nodes and to reprogram tumor micro-environments for selectively enhanced entry of CTLs and Th1 cells while counteracting local accumulation of Tregs and MDSCs. The resulting treatments are being currently tested in clinical trials in melanoma, CTCL, colorectal-, prostate- , ovarian-, and brain cancers.

Dr. Kalinski is a member of the American Society for Clinical Investigation, and has won numerous awards for his contributions to cancer immunology and immunotherapy.

Copyright © 2013-2019, WSU, KCI, HFHS Immunology Focus Group